🎀 GYN Oncology — 2026-W42

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

First-in-human phase 1 trial of the FRα-targeting ADC sofetabart mipitecan in heavily pretreated, largely platinum-resistant high-grade ovarian cancer, published in Annals of Oncology. Shows encouraging responses regardless of FRα expression and after prior mirvetuximab with a manageable toxicity profile, supporting further development.

Narrative review of novel therapies for platinum-resistant ovarian cancer, published in Gynecologic Oncology. Highlights that the disease is heterogeneous and that several new agents confer survival benefit, underscoring the role of biomarkers and toxicity management.

Small single-center retrospective review of mirvetuximab soravtansine in heavily pretreated recurrent low-grade serous ovarian carcinoma, published in Int J Gynecol Cancer. Offers early real-world efficacy and safety data in a rare, chemo-resistant subtype, though the small size limits conclusions.

Single-arm phase 2 in treatment-naive, unresectable HRD-positive high-grade serous ovarian cancer, published in Lancet Oncol. Explores chemotherapy-free neoadjuvant niraparib before interval debulking, an early signal that needs randomized confirmation.

Open-label phase 1/2 dose-finding study of a folate receptor alpha antibody-drug conjugate in pretreated advanced solid tumors, mainly ovarian and endometrial cancer, published in Gynecologic Oncology. Interstitial lung disease was a key toxicity, mitigated by dosing and schedule changes, informing the dose for further development.

Single-arm phase 2 basket cohort of letrozole plus ribociclib in heavily pre-treated, hormone receptor-positive, platinum-resistant ovarian cancer, published in Int J Gynecol Cancer. Showed very limited activity, suggesting this combination is unlikely to be a useful option in this unselected setting.

Protocol for a prospective single-arm multicenter study of niraparib maintenance in women of African ancestry with newly diagnosed advanced ovarian cancer, published in Frontiers in Oncology. No results yet; aims to address safety and tolerability in an underrepresented population.

Retrospective real-world cohort in dMMR/MSI-H advanced or recurrent endometrial cancer, published in Gynecol Oncol. Suggests first-line pembrolizumab monotherapy is associated with longer treatment duration and time to next treatment than carboplatin-paclitaxel, supporting its use in routine practice.

Cross-sectional survey of gynecologic oncology professionals across Latin America on molecular classification and access to modern therapies in endometrial cancer, published in Int J Gynecol Cancer. Highlights gaps between biomarker availability and use of immunotherapy and other therapies, informing access and implementation efforts.